Skip to main content
Top
Published in: Rheumatology International 8/2006

01-06-2006 | Original article

The protective effects of incadronate on inflammation and joint destruction in established rat adjuvant arthritis

Authors: Hongpu Zhao, Shangli Liu, Dongsheng Huang, Qiuyu Xu, Toshihide Shuto, Yukihide Iwamoto

Published in: Rheumatology International | Issue 8/2006

Login to get access

Abstract

The effects of a new generation bisphosphonate, incadronate, in established adjuvant arthritis rats were evaluated according to the arthritis index, hind paw volume, and radiological and histopathological examinations. Incadronate suppressed the radiological and histopathological changes of hind paws, as well as the joint swelling in a dose-dependent manner. In contrast, the arthritis control rats showed drastic joint inflammation, marked destruction of bone and articular cartilage. The remains of articular cartilage lost Safranin O staining, and were attached with numerous TRAP-positive multinuclear cells. Some of resorption lacunas could be seen at the cartilage matrix nearby the TRAP-positive multinuclear cells. As regards the chondroprotective effects of bisphosphonates, we speculate that it is probably concerned with the inhibition of the chondroclasts. These data indicate that bisphosphonates may be a class of effective agent that can be considered for treatment of various arthritic conditions, including human rheumatoid arthritis.
Literature
1.
2.
go back to reference Harinck HI, Papapoulos SE, Blanksma HJ, Moolenaar AJ, Vermeij P, Bijvoet OL (1987) Paget’s disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). Br Med J 295:1301–1305 Harinck HI, Papapoulos SE, Blanksma HJ, Moolenaar AJ, Vermeij P, Bijvoet OL (1987) Paget’s disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). Br Med J 295:1301–1305
3.
go back to reference Thiebaud D, Jaeger P, Gobelet C, Jacquet AF, Burckhardt P (1988) A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget’s disease of bone. Am J Med 85:207–212PubMedCrossRef Thiebaud D, Jaeger P, Gobelet C, Jacquet AF, Burckhardt P (1988) A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget’s disease of bone. Am J Med 85:207–212PubMedCrossRef
4.
go back to reference Body JJ, Mancini I (2003) Treatment of tumor-induced hypercalcemia: a solved problem? Expert Rev Anticancer Ther 3:241–246PubMedCrossRef Body JJ, Mancini I (2003) Treatment of tumor-induced hypercalcemia: a solved problem? Expert Rev Anticancer Ther 3:241–246PubMedCrossRef
5.
go back to reference Body JJ (2000) Current and future directions in medical therapy: hypercalcemia. Cancer 88(Suppl):3054–3058PubMedCrossRef Body JJ (2000) Current and future directions in medical therapy: hypercalcemia. Cancer 88(Suppl):3054–3058PubMedCrossRef
6.
go back to reference Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH (1990) Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322:1265–1271PubMed Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH (1990) Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322:1265–1271PubMed
7.
go back to reference Eggelmeijer F, Papapoulos SE, van Paassen HC, Dijkmans BA, Breedveld FC (1994) Clinical and biochemical response to single infusion of pamidronate in patients with active rheumatoid arthritis: a double blind placebo controlled study. J Rheumatol 21:2016–2020PubMed Eggelmeijer F, Papapoulos SE, van Paassen HC, Dijkmans BA, Breedveld FC (1994) Clinical and biochemical response to single infusion of pamidronate in patients with active rheumatoid arthritis: a double blind placebo controlled study. J Rheumatol 21:2016–2020PubMed
8.
go back to reference Cantatore FP, Acquista CA, Pipitone V (1999) Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate. J Rheumatol 26:2318–2323PubMed Cantatore FP, Acquista CA, Pipitone V (1999) Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate. J Rheumatol 26:2318–2323PubMed
9.
go back to reference Havdrup T, Hulth A, Telhag H (1976) The subchondral bone in osteoarthritis and rheumatoid arthritis of the knee. A histological and microradiographical study. Acta Orthop Scand 47:345–350PubMedCrossRef Havdrup T, Hulth A, Telhag H (1976) The subchondral bone in osteoarthritis and rheumatoid arthritis of the knee. A histological and microradiographical study. Acta Orthop Scand 47:345–350PubMedCrossRef
10.
go back to reference Bromley M, Woolley DE (1984) Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum 27:968–975PubMedCrossRef Bromley M, Woolley DE (1984) Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum 27:968–975PubMedCrossRef
11.
go back to reference Eggelmeijer F, Papapoulos SE, van Paassen HC, Dijkmans BA, Valkema R, Westedt ML, Landman JO, Pauwels EK, Breedveld FC (1996) Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. Arthritis Rheum 39:396–402PubMedCrossRef Eggelmeijer F, Papapoulos SE, van Paassen HC, Dijkmans BA, Valkema R, Westedt ML, Landman JO, Pauwels EK, Breedveld FC (1996) Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. Arthritis Rheum 39:396–402PubMedCrossRef
12.
go back to reference Maccagno A, Di GE, Roldan EJ, Caballero LE, Perez LA (1994) Double blind radiological assessment of continuous oral pamidronic acid in patients with rheumatoid arthritis. Scand J Rheumatol 23:211–214PubMedCrossRef Maccagno A, Di GE, Roldan EJ, Caballero LE, Perez LA (1994) Double blind radiological assessment of continuous oral pamidronic acid in patients with rheumatoid arthritis. Scand J Rheumatol 23:211–214PubMedCrossRef
13.
go back to reference Barbier A, Breliere JC, Remandet B, Roncucci R (1986) Studies on the chronic phase of adjuvant arthritis: effect of SR 41319, a new diphosphonate. Ann Rheum Dis 45:67–74PubMedCrossRef Barbier A, Breliere JC, Remandet B, Roncucci R (1986) Studies on the chronic phase of adjuvant arthritis: effect of SR 41319, a new diphosphonate. Ann Rheum Dis 45:67–74PubMedCrossRef
14.
go back to reference Osterman T, Kippo K, Lauren L, Hannuniemi R, Sellman R (1994) Effect of clodronate on established adjuvant arthritis. Rheumatol Int 14:139–147PubMedCrossRef Osterman T, Kippo K, Lauren L, Hannuniemi R, Sellman R (1994) Effect of clodronate on established adjuvant arthritis. Rheumatol Int 14:139–147PubMedCrossRef
15.
go back to reference Podworny NV, Kandel RA, Renlund RC, Grynpas MD (1999) Partial chondroprotective effect of zoledronate in a rabbit model of inflammatory arthritis. J Rheumatol 26:1972–1982PubMed Podworny NV, Kandel RA, Renlund RC, Grynpas MD (1999) Partial chondroprotective effect of zoledronate in a rabbit model of inflammatory arthritis. J Rheumatol 26:1972–1982PubMed
16.
go back to reference Zhao H, Shuto T, Hirata G, Iwamoto Y (2000) Aminobisphosphonate (YM175) inhibits bone destruction in rat adjuvant arthritis. J Orthop Sci 5:397–403PubMed Zhao H, Shuto T, Hirata G, Iwamoto Y (2000) Aminobisphosphonate (YM175) inhibits bone destruction in rat adjuvant arthritis. J Orthop Sci 5:397–403PubMed
17.
go back to reference Matsuo A, Shuto T, Hirata G, Satoh H, Matsumoto Y, Zhao H, Iwamoto Y (2003) Antiinflammatory and chondroprotective effects of the aminobisphosphonate incadronate (YM175) in adjuvant induced arthritis. J Rheumatol 30:1280–1290PubMed Matsuo A, Shuto T, Hirata G, Satoh H, Matsumoto Y, Zhao H, Iwamoto Y (2003) Antiinflammatory and chondroprotective effects of the aminobisphosphonate incadronate (YM175) in adjuvant induced arthritis. J Rheumatol 30:1280–1290PubMed
18.
go back to reference Kinne RW, Schmidt-Weber CB, Hoppe R, Buchner E, Palombo-Kinne E, Nurnberg E, Emmrich F (1995) Long-term amelioration of rat adjuvant arthritis following systemic elimination of macrophages by clodronate-containing liposomes. Arthritis Rheum 38:1777–1790PubMedCrossRef Kinne RW, Schmidt-Weber CB, Hoppe R, Buchner E, Palombo-Kinne E, Nurnberg E, Emmrich F (1995) Long-term amelioration of rat adjuvant arthritis following systemic elimination of macrophages by clodronate-containing liposomes. Arthritis Rheum 38:1777–1790PubMedCrossRef
19.
go back to reference Nishikawa M, Akatsu T, Katayama Y, Yasutomo Y, Kado S, Kugal N, Yamamoto M, Nagata N (1996) Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone 18:9–14PubMedCrossRef Nishikawa M, Akatsu T, Katayama Y, Yasutomo Y, Kado S, Kugal N, Yamamoto M, Nagata N (1996) Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone 18:9–14PubMedCrossRef
20.
go back to reference Nishikawa M, Yamamoto M, Murakami T, Akatsu T, Kugai N, Nagata N (1998) A third-generation bisphosphonate, YM175, inhibits osteoclast formation in murine cocultures by inhibiting proliferation of precursor cells via supporting cell-dependent mechanisms. J Bone Miner Res13:986–995CrossRef Nishikawa M, Yamamoto M, Murakami T, Akatsu T, Kugai N, Nagata N (1998) A third-generation bisphosphonate, YM175, inhibits osteoclast formation in murine cocultures by inhibiting proliferation of precursor cells via supporting cell-dependent mechanisms. J Bone Miner Res13:986–995CrossRef
21.
go back to reference Ito M, Amizuka N, Nakajima T, Ozawa H (1999) Ultrastructural and cytochemical studies on cell death of osteoclasts induced by bisphosphonate treatment. Bone 25:447–452PubMedCrossRef Ito M, Amizuka N, Nakajima T, Ozawa H (1999) Ultrastructural and cytochemical studies on cell death of osteoclasts induced by bisphosphonate treatment. Bone 25:447–452PubMedCrossRef
22.
go back to reference Lehmann HJ, Mouritzen U, Christgau S, Cloos PA, Christiansen C (2002) Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products. Ann Rheum Dis 61:530–533PubMedCrossRef Lehmann HJ, Mouritzen U, Christgau S, Cloos PA, Christiansen C (2002) Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products. Ann Rheum Dis 61:530–533PubMedCrossRef
23.
go back to reference Garnero P, Christgau S, Delmas PD (2001) The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget’s disease of bone. Bone 28:461–464PubMedCrossRef Garnero P, Christgau S, Delmas PD (2001) The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget’s disease of bone. Bone 28:461–464PubMedCrossRef
24.
go back to reference Teronen O, Heikkila P, Konttinen YT, Laitinen M, Salo T, Hanemaaijer R, Teronen A, Maisi P, Sorsa T (1999) MMP inhibition and downregulation by bisphosphonates. Ann N Y Acad Sci 878:453–465PubMedCrossRef Teronen O, Heikkila P, Konttinen YT, Laitinen M, Salo T, Hanemaaijer R, Teronen A, Maisi P, Sorsa T (1999) MMP inhibition and downregulation by bisphosphonates. Ann N Y Acad Sci 878:453–465PubMedCrossRef
25.
go back to reference Van Offel JF, Schuerwegh AJ, Bridts CH, Stevens WJ, De Clerck LS (2002) Effect of bisphosphonates on viability, proliferation, and dexamethasone-induced apoptosis of articular chondrocytes. Ann Rheum Dis 61:925–928PubMedCrossRef Van Offel JF, Schuerwegh AJ, Bridts CH, Stevens WJ, De Clerck LS (2002) Effect of bisphosphonates on viability, proliferation, and dexamethasone-induced apoptosis of articular chondrocytes. Ann Rheum Dis 61:925–928PubMedCrossRef
26.
go back to reference Johnson WJ, DiMartino MJ, Hanna N (1986) Macrophage activation in rat models of inflammation and arthritis: determination of markers of stages of activation. Cell Immunol 103:54–64PubMedCrossRef Johnson WJ, DiMartino MJ, Hanna N (1986) Macrophage activation in rat models of inflammation and arthritis: determination of markers of stages of activation. Cell Immunol 103:54–64PubMedCrossRef
27.
go back to reference Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13:581–589PubMedCrossRef Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13:581–589PubMedCrossRef
28.
go back to reference Nakamura M, Ando T, Abe M, Kumagai K, Endo Y (1996) Contrast between effects of aminobisphosphonates and non-aminobisphosphonates on collagen-induced arthritis in mice. Br J Pharmacol 119:205–212PubMed Nakamura M, Ando T, Abe M, Kumagai K, Endo Y (1996) Contrast between effects of aminobisphosphonates and non-aminobisphosphonates on collagen-induced arthritis in mice. Br J Pharmacol 119:205–212PubMed
29.
go back to reference Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB (2001) Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28:524–531PubMedCrossRef Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB (2001) Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28:524–531PubMedCrossRef
30.
go back to reference Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB (2000) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15:613–620PubMedCrossRef Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB (2000) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15:613–620PubMedCrossRef
31.
go back to reference Komatsubara S, Mori S, Mashiba T, Ito M, Li J, Kaji Y, Akiyama T, Miyamoto K, Cao Y, Kawanishi J, Norimatsu H (2003) Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J Bone Miner Res 18:512–520PubMedCrossRef Komatsubara S, Mori S, Mashiba T, Ito M, Li J, Kaji Y, Akiyama T, Miyamoto K, Cao Y, Kawanishi J, Norimatsu H (2003) Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J Bone Miner Res 18:512–520PubMedCrossRef
Metadata
Title
The protective effects of incadronate on inflammation and joint destruction in established rat adjuvant arthritis
Authors
Hongpu Zhao
Shangli Liu
Dongsheng Huang
Qiuyu Xu
Toshihide Shuto
Yukihide Iwamoto
Publication date
01-06-2006
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 8/2006
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-005-0061-8

Other articles of this Issue 8/2006

Rheumatology International 8/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.